Table 3.
Tumor response of surufatinib plus toripalimab (efficacy evaluable population)
| Surufatinib 200 mg QD + toripalimab 240 mg Q3W (n = 6) n (%) |
Surufatinib 250 mg QD + toripalimab 240 mg Q3W (n = 11) n (%) |
Surufatinib 300 mg QD + toripalimab 240 mg Q3W (n = 12) n (%) |
Total (n = 29) n (%) |
|
|---|---|---|---|---|
| Confirmed best overall response (based on RECIST v1.1) | ||||
| CR | 1 (16.7) | 0 (0.0) | 0 (0.0) | 1 (3.4) |
| PR | 0 (0.0) | 5 (45.5) | 1 (8.3) | 6 (20.7) |
| SD | 2 (33.3) | 6 (54.5) | 8 (66.7) | 16 (55.2) |
| PD | 3 (50.0) | 0 (0.0) | 3 (25.0) | 6 (20.7) |
| ORRa | 1 (16.7) | 5 (45.5) | 1 (8.3) | 7 (24.1) |
| 95% CI of ORR | 0.4–64.1 | 16.7–76.6 | 0.2–38.5 | 10.3–43.5 |
| DCRb | 3 (50.0) | 11 (100.0) | 9 (75.0) | 23 (79.3) |
| 95% CI of DCR | 11.8–88.2 | 71.5–100.0 | 42.8–94.5 | 60.3–92.0 |
CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease control rate, CI confidence interval, RECIST Response Evaluation Criteria in Solid Tumors
aORR was defined as the proportion of patients with confirmed best overall response of CR or PR
bDCR was defined as the proportion of patients with best overall response of CR or PR or SD